The Belgian biotech is pleased with the launch of its rheumatoid arthritis drug in Germany and the Netherlands and it has also secured a broad label from NICE.

The Swiss major envisions developing an accessible in vivo gene therapy for SCD that could potentially be administered once directly to the patient without the need to modify cells in a lab.

Rheumatologists may be more cautious about prescribing biosimilars to Humira than they have been for biosimilars to Avastin and Herceptin. But pharmacy benefit managers will have more influence over Humira biosimilars, which adds a new dynamic to the follow-on market.

Biocon Biologics strikes deal with the Clinton Health Access Initiative to provide cost-effective alternatives to pricey reference biologics, beginning with trastuzumab and pegfilgrastim. Savings of over 59% for buyers are expected in some cases.

The notion that pharma R&D caters for western populations first and only much later are the fruits of that research made available for low-income countries is slowly but surely changing, according to a high-profile review of access to drugs.

A conditional marketing authorization for AstraZeneca/Oxford's COVID-19 vaccine came just hours after the European Medicines Agency’s CHMP voted unanimously to recommend it on Friday.

Executives share their expectations and hopes around the multi-faceted topic of patient access to medicines. From health inequities to value assessment and reimbursement trends, expectations for change abound.

China's latest round of reimbursement decisions show multinationals including AstraZeneca, BMS and Roche won’t be receiving national coverage for their latest immuno-oncology drugs any time soon.

The drug enters the increasingly competitive space of CD20-targeting therapies for multiple sclerosis, with two agents already approved.